WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a 1-for-50 reverse stock split of its common stock. The company’s board approved the move following authorization granted by stockholders during a Special Meeting on February 3, 2025. This decision, effective February 20, 2025, at 5:00 p.m. Eastern Time, is designed to boost the stock’s per-share price and ensure compliance with Nasdaq’s $1.00 minimum bid price requirement.
Starting February 21, 2025, the company’s common stock will trade on a split-adjusted basis on Nasdaq under the ticker symbol “WINT.” The reverse stock split will reduce the number of outstanding shares from approximately 35 million to about 700,000, combining every fifty shares of issued and outstanding common stock into one. The par value of the stock, at $0.001, will remain unchanged.
This move carries practical implications for shareholders. Proportional adjustments will be applied to equity awards, warrants, and convertible securities, ensuring consistency in share structure. Additionally, no fractional shares will be issued, with fractional entitlements instead receiving proportional cash payments.
The company has appointed Continental Stock Transfer and Trust Company as the exchange agent for this process. For stockholders holding shares electronically or in brokerage accounts, no action is required; positions will update automatically.
Windtree Therapeutics emphasized that this strategic move reflects its dedication to retaining its Nasdaq listing while preparing the company for future opportunities.
With this adjustment, Windtree is taking steps to secure compliance and execute plans for its financial stability. By leveraging this restructuring, the company aims to enhance its market presence while pursuing its long-term vision in the biopharmaceutical space.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.